This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

99mTc-MIP-1436

Progenics Pharmaceuticals, Inc.

Drug Names(s): Technium-99m-labeled-MIP-1436

Description: 99mTc-MIP-1436 is a carbonic anhydrase (CA) IX inhibitor.

Deal Structure: Progenics and Molecular Insight
In January 2013, Progenics announced that it has acquired Molecular Insight. Under the terms of the all-stock transaction, Progenics exchanged 4,566,210 shares of its common stock (8.9% of the total outstanding post-transaction shares) for all of the outstanding shares of Molecular Insight, which will become a wholly-owned subsidiary of Progenics. Molecular Insight has no debt. Progenics may make additional milestone payments to the former owners of Molecular Insight based on future commercial sales of the company's compounds. No royalties are due to the former owners of Molecular Insight.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug